CD8+ T-cell percentage increases in diffuse large B-cell lymphoma patients receiving mannatide combined with standard regimens.

Published in: Journal of clinical pharmacy and therapeutics (2021)

CD3+ CD8+ T-cell percentage increased in DLBCL patients receiving MT treatment. Further studies are required to determine the clinical benefits of MT.

Keyphrases

diffuse large b cell lymphoma
epstein barr virus
combination therapy
replacement therapy
smoking cessation